V-Go Disposable Insulin Delivery Device

 Valeritas, a medical technology company committed to the development and commercialization of innovative drug delivery solutions, has received CE Mark approval for its V-Go Disposable Insulin Delivery Device as well as ISO 13485: 2003 Quality Management System Certification. The V-Go is designed to provide simple basal-bolus therapy for adults who require insulin therapy.
The V-Go is the first simple, fully disposable device designed and approved for the delivery of basal-bolus insulin therapy for adults with diabetes. The V-Go provides a continuous preset basal rate of insulin and allows for on-demand bolus dosing around mealtimes, thereby providing an alternative to taking multiple daily insulin injections.
The V-Go is engineered to simplify basal-bolus insulin therapy for the millions of people suffering from type 2 diabetes. The V-Go is small and lightweight and worn under the patients' clothing. It measures just 2.4 x 1.3 x 0.5 inches and weighs approximately 1 ounce when filled with insulin. Patients apply a new V-Go to the skin daily for one 24-hour period. The V-Go is not electronic, making it easy to operate and use.
The V-Go is filled with insulin using a very simple disposable point-of-care filling accessory—the V-Go EZ Fill (which will be included with each monthly supply of V-Go devices). A separate prescription for insulin is required for use with the V-Go.
 Humalog (Eli Lilly and Co.) and NovoLog (Novo Nordisk) have both been tested by Valeritas and found safe for use with the V-Go Disposable Insulin Delivery Device. In December 2010, Valeritas received FDA 510(k) clearance for the V-Go's use with Humalog and in February 2011 received FDA 510(k) clearance for use with NovoLog.
In addition to the V-Go, the Valeritas delivery technology portfolio includes the h-Patch for the delivery of other compounds in addition to insulin, the Mini-Ject Pre- Filled Needle-Free Delivery System, and the Micro-Trans Microneedle Delivery System. These technologies, when combined with certain compounds, are designed to enhance the delivery of a variety of injectable drugs resulting in improved patient acceptance and outcomes.
 Source: Valeritas (www.valeritas.com or www.go-vgo.com)
Prime Hype DF 2016 EP